Published in Lancet on August 05, 2006
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell (2014) 2.36
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. J Infect Dis (2008) 2.21
Modeling spinal muscular atrophy in Drosophila. PLoS One (2008) 1.71
A national survey of the impact of rapid scale-up of antiretroviral therapy on health-care workers in Malawi: effects on human resources and survival. Bull World Health Organ (2007) 1.53
Novel approaches to inhibiting HIV-1 replication. Antiviral Res (2009) 1.48
Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol (2013) 1.33
Enumeration of CD4+ T-cells using a portable microchip count platform in Tanzanian HIV-infected patients. PLoS One (2011) 1.32
The feasibility of preventing mother-to-child transmission of HIV using peer counselors in Zimbabwe. AIDS Res Ther (2008) 1.23
Neisseria gonorrhoeae-induced human defensins 5 and 6 increase HIV infectivity: role in enhanced transmission. J Immunol (2008) 1.15
Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets (2009) 1.13
Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection. Immunology (2008) 1.13
Mucosal immunology of the genital and gastrointestinal tracts and HIV-1 infection. J Reprod Immunol (2009) 1.06
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob Agents Chemother (2011) 1.03
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine (2009) 1.03
Spatial visualization of multivariate datasets: an analysis of STD and HIV/AIDS diagnosis rates and socioeconomic context using ring maps. Public Health Rep (2011) 1.01
'Stuck in the quagmire of an HIV ghetto': the meaning of stigma in the lives of older black gay and bisexual men living with HIV in New York City. Cult Health Sex (2011) 0.97
A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol (2010) 0.96
Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J Infect Dis (2009) 0.94
EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob Agents Chemother (2010) 0.93
Recent progress in antiretrovirals--lessons from resistance. Drug Discov Today (2008) 0.92
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. J Antimicrob Chemother (2011) 0.90
Evidence of a novel RNA secondary structure in the coding region of HIV-1 pol gene. RNA (2008) 0.89
Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother (2012) 0.89
Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends Immunol (2011) 0.89
Information-motivation-behavioral skills barriers associated with intentional versus unintentional ARV non-adherence behavior among HIV+ patients in clinical care. AIDS Care (2010) 0.88
The chemokine receptor CCR5, a therapeutic target for HIV/AIDS antagonists, is critical for recovery in a mouse model of Japanese encephalitis. PLoS One (2012) 0.87
Association between living with children and adherence to highly active antiretroviral therapy in the Women's Interagency HIV Study. Pediatrics (2008) 0.87
A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi. PLoS One (2014) 0.86
Early skewed distribution of total and HIV-specific CD8+ T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression. PLoS One (2014) 0.86
Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process. Mol Biol Int (2012) 0.85
SAMMA, a mandelic acid condensation polymer, inhibits dendritic cell-mediated HIV transmission. FEBS Lett (2007) 0.85
Contraception and HIV infection in women. Hum Reprod Update (2008) 0.85
HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells. J Immunol (2011) 0.84
HIV infection and cardiovascular risk in black South Africans. Cardiovasc J Afr (2011) 0.84
The lupane-type triterpene 30-oxo-calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti-chemotactic activities. J Biol Chem (2009) 0.83
Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses (2012) 0.82
Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects. Curr HIV Res (2012) 0.82
Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets. Mol Interv (2009) 0.80
Seroprevalence of Toxoplasma gondii Infection among HIV/AIDS Patients in Eastern China. Korean J Parasitol (2016) 0.80
Functional genomics analyses of differential macaque peripheral blood mononuclear cell infections by human immunodeficiency virus-1 and simian immunodeficiency virus. Virology (2007) 0.80
Identifying the age cohort responsible for transmission in a natural outbreak of Bordetella bronchiseptica. PLoS Pathog (2010) 0.79
Contraceptive Use and Uptake of HIV-Testing among Sub-Saharan African Women. PLoS One (2016) 0.79
Candida colonisation in asymptomatic HIV patients attending a tertiary hospital in Benin City, Nigeria. Libyan J Med (2013) 0.79
Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? Virology (Auckl) (2013) 0.79
Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects. Acta Naturae (2011) 0.78
HIV-1 Nef and T-cell activation: a history of contradictions. Future Virol (2013) 0.78
National Responses to HIV/AIDS and Non-Communicable Diseases in Developing Countries: Analysis of Strategic Parallels and Differences. J Public Health Res (2014) 0.77
HSV type 2 infection increases HIV DNA detection in vaginal tissue of mice expressing human CD4 and CCR5. AIDS Res Hum Retroviruses (2009) 0.77
Differential clinical outcome of dengue infection among patients with and without HIV infection: a matched case-control study. Am J Trop Med Hyg (2015) 0.77
The impact of HIV-associated anaemia on the incidence of red blood cell transfusion: implications for blood services in HIV-endemic countries. Transfus Apher Sci (2014) 0.77
Identification of a novel sulfonamide non-nucleoside reverse transcriptase inhibitor by a phenotypic HIV-1 full replication assay. PLoS One (2013) 0.76
Benefits of leptin therapy in HIV patients. Indian J Endocrinol Metab (2012) 0.76
Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease. Antimicrob Agents Chemother (2016) 0.75
Understanding the effects of different HIV transmission models in individual-based microsimulation of HIV epidemic dynamics in people who inject drugs. Epidemiol Infect (2016) 0.75
Non-sterile injections, contaminated blood, and the spread of HIV. Lancet (2006) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
Conserved Interaction of Lentiviral Vif Molecules with HIV-1 Gag and Differential Effects of Species-Specific Vif on Virus Production. J Virol (2017) 0.75
Epidemiologic characteristics of HIV-positive patients referring to behavioral diseases consultation center in Shiraz, Iran. Med J Islam Repub Iran (2014) 0.75
CD4 counts: a strong indicator of retinal and ocular lesions in HIV disease. Med J Armed Forces India (2011) 0.75
Repression of Proteases and Hsp90 Chaperone Expression Induced by an Antiretroviral in Virulent Environmental Strains of Cryptococcus neoformans. Microb Ecol (2016) 0.75
Morphological and immunological changes in the skin of autopsied women with AIDS. Virchows Arch (2012) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature (2004) 17.56
HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A (2002) 17.22
The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science (2005) 17.00
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
HIV-1 integration in the human genome favors active genes and local hotspots. Cell (2002) 12.60
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell (2001) 12.00
Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS (2004) 11.18
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis (1999) 9.81
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem (2001) 8.96
Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. AIDS (2005) 8.71
A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med (1994) 8.52
HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat Med (2001) 8.38
Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol (2004) 8.27
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics (2002) 7.10
The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04
HIV decline associated with behavior change in eastern Zimbabwe. Science (2006) 6.98
Scaling up access to antiretroviral treatment in southern Africa: who will do the job? Lancet (2004) 6.84
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci U S A (2006) 6.82
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol (2005) 5.92
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
How does male circumcision protect against HIV infection? BMJ (2000) 5.64
A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science (2000) 5.52
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
T cell dynamics in HIV-1 infection. Annu Rev Immunol (2001) 5.29
Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev (2002) 5.29
GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol (2006) 5.28
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
The impact of migration on HIV-1 transmission in South Africa: a study of migrant and nonmigrant men and their partners. Sex Transm Dis (2003) 5.09
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Retroviral restriction by APOBEC proteins. Nat Rev Immunol (2004) 5.00
Intrinsic immunity: a front-line defense against viral attack. Nat Immunol (2004) 4.95
TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol (2005) 4.89
A role for LEDGF/p75 in targeting HIV DNA integration. Nat Med (2005) 4.88
Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol (2004) 4.76
A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis (2001) 4.73
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature (2006) 4.59
High acceptability of voluntary counselling and HIV-testing but unacceptable loss to follow up in a prevention of mother-to-child HIV transmission programme in rural Malawi: scaling-up requires a different way of acting. Trop Med Int Health (2005) 4.55
Immune restoration disease after antiretroviral therapy. AIDS (2004) 4.54
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet (2005) 4.51
Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 4.41
Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet (2000) 4.39
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
Late budding domains and host proteins in enveloped virus release. Virology (2006) 4.11
Concurrent sexual partnerships help to explain Africa's high HIV prevalence: implications for prevention. Lancet (2004) 4.11
Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes--the case of Malawi. Int J Tuberc Lung Dis (2005) 4.04
HIV/AIDS in women: an expanding epidemic. Science (2005) 3.68
Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol (2002) 3.66
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol (2006) 3.63
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. J Infect Dis (2005) 3.50
HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis (2005) 3.49
Complementary function of the two catalytic domains of APOBEC3G. Virology (2005) 3.45
Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med (2001) 3.37
Role of ESCRT-I in retroviral budding. J Virol (2003) 3.36
Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med (2002) 3.31
HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science (1998) 3.28
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A (2006) 3.26
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis (2004) 3.23
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med (2005) 3.17
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology (1994) 3.05
Acceptability of adult male circumcision for sexually transmitted disease and HIV prevention in Zimbabwe. Sex Transm Dis (2005) 3.00
A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLoS Med (2005) 2.90
A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep (2006) 2.81
HIV-1 Langerhans' cell tropism associated with heterosexual transmission of HIV. Science (1996) 2.79
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS (2004) 2.78
Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings. Lancet (2005) 2.73
G-->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol (2005) 2.61
Transcriptionally active genome regions are preferred targets for retrovirus integration. J Virol (1990) 2.59
Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon. J Acquir Immune Defic Syndr (2005) 2.55
Mode of infant feeding and HIV infection in children in a program for prevention of mother-to-child transmission in Uganda. AIDS (2005) 2.48
Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J Virol (2005) 2.47
Migration and HIV-1 seroprevalence in a rural Ugandan population. AIDS (1995) 2.45
Desperately seeking targets: the ethics of routine HIV testing in low-income countries. Bull World Health Organ (2006) 2.43
Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. Lancet (2003) 2.38
Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (2003) 2.32
The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. Structure (2006) 2.32
Population-based study of fertility in women with HIV-1 infection in Uganda. Lancet (1998) 2.29
Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet (2003) 2.23
Seroprevalence of HIV infection in rural South Africa. AIDS (1992) 2.22
Identification of microRNAs of the herpesvirus family. Nat Methods (2005) 12.98
Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med (2010) 10.90
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Recognition of bacterial glycosphingolipids by natural killer T cells. Nature (2005) 6.38
Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med (2011) 5.31
Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet (2005) 4.21
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Establishing a cohort at high risk of HIV infection in South Africa: challenges and experiences of the CAPRISA 002 acute infection study. PLoS One (2008) 3.40
The changing face of HIV in China. Nature (2008) 3.39
Achieving the health Millennium Development Goals for South Africa: challenges and priorities. Lancet (2009) 3.35
Retracted Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science (2002) 2.81
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med (2012) 2.48
Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med (2006) 2.37
Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc Natl Acad Sci U S A (2005) 2.13
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
A case series of 104 women infected with HIV-1 via blood transfusion postnatally: high rate of HIV-1 transmission to infants through breast-feeding. J Infect Dis (2009) 2.02
HIV-1 dynamics in vivo: implications for therapy. Nat Rev Microbiol (2003) 1.94
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol (2003) 1.87
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82
Global development. Family planning and the Millennium Development Goals. Science (2010) 1.78
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A (2013) 1.76
Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china. J Virol (2004) 1.76
Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis (2012) 1.73
In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One (2011) 1.71
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A (2008) 1.59
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood (2002) 1.53
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc (2006) 1.47
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A (2010) 1.37
The changing epidemiology of HIV in 2013. Curr Opin HIV AIDS (2013) 1.31
Human immunodeficiency virus type 1 (HIV-1)-specific CD8+-T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes. J Virol (2002) 1.28
Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther (2004) 1.23
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide. Vaccine (2008) 1.19
Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients. J Virol (2010) 1.19
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries. Clin Infect Dis (2004) 1.18
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure (2010) 1.15
Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci (2004) 1.14
Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J Infect Dis (2013) 1.12
Estimating average cellular turnover from 5-bromo-2'-deoxyuridine (BrdU) measurements. Proc Biol Sci (2003) 1.11
The liver is a major organ for clearing simian immunodeficiency virus in rhesus monkeys. J Virol (2002) 1.10
Disclosure of microbicide gel use to sexual partners: influence on adherence in the CAPRISA 004 trial. AIDS Behav (2014) 1.09
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Global epidemiology of HIV-AIDS. Infect Dis Clin North Am (2007) 1.06
Adherence in the CAPRISA 004 tenofovir gel microbicide trial. AIDS Behav (2014) 1.06
Identification of novel small-molecule inhibitors of severe acute respiratory syndrome-associated coronavirus by chemical genetics. Chem Biol (2004) 1.05
Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One (2010) 1.05
Compartmentalization of surface envelope glycoprotein of human immunodeficiency virus type 1 during acute and chronic infection. J Virol (2002) 1.04
HIV prevalence among high school learners - opportunities for schools-based HIV testing programmes and sexual reproductive health services. BMC Public Health (2012) 1.04
Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol (2005) 1.03
Modeling deuterated glucose labeling of T-lymphocytes. Bull Math Biol (2002) 1.02
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One (2010) 1.01
Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J Acquir Immune Defic Syndr (2008) 0.99
Interventions to modify sexual risk behaviours for preventing HIV in homeless youth. Cochrane Database Syst Rev (2011) 0.98
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope. J Acquir Immune Defic Syndr (2013) 0.98
Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial. J Acquir Immune Defic Syndr (2012) 0.97
Natural killer cell function in women at high risk for HIV acquisition: insights from a microbicide trial. AIDS (2012) 0.96
Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'. J Acquir Immune Defic Syndr (2008) 0.93
The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol (2003) 0.93
Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. J Acquir Immune Defic Syndr (2014) 0.92
Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine (2010) 0.92
CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic Simian/Human Immunodeficiency Virus (SHIV). J Acquir Immune Defic Syndr (2002) 0.91
Antiretroviral therapy: challenges and options in South Africa. Lancet (2003) 0.91
Prevention of mother-to-child transmission of HIV-1 using highly active antiretroviral therapy in rural Yunnan, China. J Acquir Immune Defic Syndr (2010) 0.90
Synthesis and human NKT cell stimulating properties of 3-O-sulfo-alpha/beta-galactosylceramides. Bioorg Med Chem (2005) 0.89
A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One (2013) 0.87
Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial. J Clin Microbiol (2013) 0.87
Retraction of an interpretation. Science (2004) 0.87
The preventive misconception: experiences from CAPRISA 004. AIDS Behav (2014) 0.86
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Trends in HIV Prevalence in Pregnant Women in Rural South Africa. J Acquir Immune Defic Syndr (2015) 0.84
In vivo replication kinetics of a nef-deleted strain of HIV-1. AIDS (2005) 0.83
A recoding method to improve the humoral immune response to an HIV DNA vaccine. PLoS One (2008) 0.83
Experimental infection with Haemophilus ducreyi in persons who are infected with HIV does not cause local or augment systemic viral replication. J Infect Dis (2007) 0.83
Strategic addition of an N-linked glycan to a monoclonal antibody improves its HIV-1-neutralizing activity. Nat Biotechnol (2013) 0.83
Neither microbial translocation nor TLR responsiveness are likely explanations for preexisting immune activation in women who subsequently acquired HIV in CAPRISA 004. J Acquir Immune Defic Syndr (2013) 0.83
Duration of an intermittent episode of viremia. Bull Math Biol (2005) 0.82
The HIV epidemic in Southern Africa - Is an AIDS-free generation possible? Curr HIV/AIDS Rep (2014) 0.82
HIV-1 and influenza antigens synthetically linked to IgG2a Fc elicit superior humoral responses compared to unmodified antigens in mice. Vaccine (2011) 0.82
HIV-Associated Tuberculosis. Clin Dev Immunol (2010) 0.81
Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Appl Microbiol Biotechnol (2007) 0.80
CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells. J Acquir Immune Defic Syndr (2011) 0.80
Multiple-site DNA vaccination enhances immune responses in mice. Vaccine (2005) 0.79
Monitoring microbicide gel use with real-time notification of the container's opening events: results of the CAPRISA Wisebag study. AIDS Behav (2014) 0.79